{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.76","statisticalComment":"Stratified log rank","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.87","upperLimit":"89.23","value":"61.14"},{"groupId":"OG001","lowerLimit":"16.56","upperLimit":"35.12","value":"24.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"453"}],"units":"Participants"}],"description":"RFS is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma, or death (whatever the cause), whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV q2 wks and Ipilimumab placebo IV q3 wks for 4 doses then q12 wks starting at Wk 24","id":"OG000","title":"Nivolumab 3 mg/kg"},{"description":"Ipilimumab 10 mg/kg IV q3 wks for 4 doses then q12 wks starting at Wk 24 and Nivolumab placebo IV q2 wks","id":"OG001","title":"Ipilimumab 10 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"up to 114 months","title":"Recurrence-free Survival (RFS)","type":"POST_HOC","unitOfMeasure":"Months"}